Aclarion (ACON) Registration Filing summary

Company overview and business model

• Operates as a healthcare technology company leveraging Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments for low back and neck pain, targeting a $134.5B U.S. market.

• Utilizes AI for quality control and aspires to expand AI applications to clinical outcome analysis and other diagnostic areas, including brain, breast, and prostate tumors.

• Focuses initially on improving surgical outcomes for lumbar spine pain, with plans to expand to conservative therapies and neck pain diagnostics.

• Holds a portfolio of 23 U.S. patents, 17 foreign patents, and several pending applications, with key technology licensed from UCSF.

Financial performance and metrics

• Reported stockholders' equity of $1,642,177 as of June 30, 2024.

• Limited sales to date, with ongoing efforts to expand market adoption.

• Audit reports include a going concern explanatory paragraph, highlighting financial risk.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; may receive up to $2.31 million from cash exercise of warrants, to be used for working capital and general corporate purposes.

• No dividends anticipated; all funds and future earnings intended for business development and expansion.